World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
35689
World Ranking
16405
National Ranking
206

Evandro de Azambuja publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Evandro de Azambuja sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 440 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Evandro de Azambuja D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Evandro de Azambuja sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Evandro de Azambuja is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on oncology and cancer-related studies.

The scientist's work extends across several subfields, including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Genetics. Their research topics cover a range of areas such as Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Risks and Factors, Cancer Immunotherapy and Biomarkers, and Chemotherapy-induced cardiotoxicity and mitigation.

Evandro de Azambuja has published extensively with frequent contributions appearing in a number of scientific venues. These include:

  • ESMO Open
  • Annals of Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • European Journal of Cancer

Their collaboration network features several frequent co-authors, among them:

  • Matteo Lambertini
  • Martine Piccart
  • Elisa Agostinetto
  • Marco Bruzzone
  • Guilherme Nader Marta

Recent significant publications include:

  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) (2022), published in European Heart Journal
  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (2021), published in New England Journal of Medicine
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer (2021), published in Annals of Oncology
  • Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020), published in Annals of Oncology
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours (2021), published in Annals of Oncology

Best Publications

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    Gunter von Minckwitz;Marion Procter;Evandro de Azambuja;Dimitrios Zardavas

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    David Cameron;Martine J Piccart-Gebhart;Richard D Gelber;Richard D Gelber;Marion Procter

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

    Luca Gianni;Urania Dafni;Richard D Gelber;Evandro Azambuja

  • Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial

    Roberto Salgado;Carsten Denkert;Christine Campbell;Peter Savas

  • Planning cancer control in Latin America and the Caribbean

    Paul E. Goss;Brittany L. Lee;Brittany L. Lee;Tanja Badovinac-Crnjevic;Kathrin Strasser-Weippl

  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial

    Aron Goldhirsch;Richard D. Gelber;Martine J. Piccart-Gebhart;Evandro De Azambuja

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

    Evandro De Azambuja;Andrew P. Holmes;Martine Piccart-Gebhart;Eileen Holmes

  • Dissecting the Heterogeneity of Triple-Negative Breast Cancer

    Otto Metzger-Filho;Andrew M Tutt;Evandro Azambuja;Kamal S Saini

  • Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

    Thomas Eschenhagen;Thomas Force;Michael S. Ewer;Gilles W. De Keulenaer

  • An update on PARP inhibitors—moving to the adjuvant setting

    Amir Sonnenblick;Evandro de Azambuja;Hatem A. Azim;Martine Piccart

  • Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers

    Christian Widakowich;Christian Widakowich;Gilberto de Castro;Evandro de Azambuja;Evandro de Azambuja;Phuong Dinh

  • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    Martine Piccart-Gebhart;Eileen Holmes;Jośe Baselga;Evandro De Azambuja

  • Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives

    Felipe Ades;Dimitrios Zardavas;Ivana Bozovic-Spasojevic;Lina Pugliano

  • Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

    Kamal S. Saini;Kamal S. Saini;Sherene Loi;Evandro de Azambuja;Otto Metzger-Filho

  • Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

    M. Colozza;E. Azambuja;F. Cardoso;C. Sotiriou

  • Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

    Marion Procter;Thomas M. Suter;Evandro De Azambuja;Urania Dafni

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Richard D. Gelber
Richard D. Gelber Harvard University
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Marianne Paesmans
Marianne Paesmans Université Libre de Bruxelles
Giuseppe Viale
Giuseppe Viale University of Milan
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Medicine can open doors to a wide range of rewarding healthcare careers. However, not all paths require a traditional medical degree. Many students explore related online degrees that offer flexibility, affordability, and targeted expertise. For example, earning a healthcare administration degree online is a great option for those interested in leadership and management roles within the healthcare sector.

Graduate-level programs are especially valuable. Among the most affordable online mha programs, students can gain crucial skills in healthcare policy, operations, and strategy—often while still working full-time. For those aiming to specialize in nursing, some of the most affordable online dnp programs prepare graduates for advanced practice and leadership positions.

Pharmacy is another in-demand medical field. Choosing the best online pharmacy school can help kickstart a fulfilling career in pharmaceutical care. Exploring these online degree options can be a smart, flexible pathway for those passionate about making a difference in healthcare.

Best Scientists Citing Evandro de Azambuja

Trending Scientists

Recently Published Articles